Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phyllodes tumor of the breast.
Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, Lacroix M, Gutierrez C, Senkus E, Christie D, Drumea K, Lagneau E, Kadish SP, Scandolaro L, Azria D, Ozsahin M. Belkacémi Y, et al. Among authors: bousquet g. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):492-500. doi: 10.1016/j.ijrobp.2007.06.059. Epub 2007 Oct 10. Int J Radiat Oncol Biol Phys. 2008. PMID: 17931796
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment.
Bui TO, Angeli E, El Bouchtaoui M, Gapihan G, Dao VT, Paris J, Leboeuf C, Soussan M, Villarese P, Ziol M, Van Glabeke E, Le TH, Feugeas JP, Janin A, Bousquet G. Bui TO, et al. Among authors: bousquet g. Exp Hematol Oncol. 2023 May 15;12(1):46. doi: 10.1186/s40164-023-00408-z. Exp Hematol Oncol. 2023. PMID: 37189165 Free PMC article.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
TP53 status and response to treatment in breast cancers.
Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. Varna M, et al. Among authors: bousquet g. J Biomed Biotechnol. 2011;2011:284584. doi: 10.1155/2011/284584. Epub 2011 May 9. J Biomed Biotechnol. 2011. PMID: 21760703 Free PMC article. Review.
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, Blay JY, Penel N; French Sarcoma Group (GSF/GETO). Ray-Coquard I, et al. Among authors: bousquet g. Oncologist. 2012;17(2):260-6. doi: 10.1634/theoncologist.2011-0237. Epub 2012 Jan 27. Oncologist. 2012. PMID: 22285963 Free PMC article. Clinical Trial.
169 results